Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy with Elranatamab in Patients with High-risk Multiple Myeloma
NCT06207799
Age 18 - 75
Sex Both
Phase Phase 2
Third Opinion Trial Synopsis
In this clinical study, researchers are exploring a new treatment approach for patients with a specific type of blood cancer. The study is unique because it combines two different treatment methods to see if they work better together than separately. Here are some key points about the study:
- The study focuses on a combination of therapies that target the cancer cells in different ways.
- Participants will receive both treatments, which may help improve their overall health and response to therapy.
- This approach aims to enhance the effectiveness of the treatment, potentially leading to better outcomes for patients.
- Researchers are looking at how well this combination works compared to standard treatments.
- The study includes a diverse group of participants to ensure the findings are applicable to a wide range of patients.
Third Opinion AI Generated Synopsis
Trial Summary
To learn if giving elranatamab before and after an autologous stem cell transplant (ASTC) can help to control newly diagnosed, high-risk MM. An ASTC is a type of transplant in which a person's own stem cells are collected, preserved, and returned to them.
To learn if giving elranatamab before and after an autologous stem cell transplant (ASTC) can help to control newly diagnosed, high-risk MM. An ASTC is a type of transplant in which a person's own stem cells are collected, preserved, and returned to them.
from ClinicalTrials.gov
Locations & Contact
Fill out the form and to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts:
